AbbVie’s Venclexta granted full US approval in AML
The US Food and Drug Administration (FDA) has fully approved AbbVie’s Venclexta in acute myeloid leukaemia (AML).
We use necessary cookies to make our site work. We'd also like to set analytical cookies to help us improve our service, but we'd like your permission first. Please choose which cookies you're happy for us to set.